In OPCs subjected to tumor necrosis factor alpha (TNF-α) treatment, PEALut reduces the acute-phase protein serum amyloid A1 (SAA1) expression [22], a gene coding for SAA protein that was found to be elevated in peripheral blood of patients with relapsing–remitting MS over a 3-month period [23]. The gene discussed is TNF; the disease is myeloid sarcoma.